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Inhibition of biological activity of multiplication-stimulating
activity by binding to its carrier protein
(somatomedin/cell growth/somatomedin binding protein)

DANIEL J. KNAUER AND GARY L. SMITH
School of Life Sciences, University of Nebraska, Lincoln, Nebraska 68588

Communicated by Howard M. Temin, August 4,1980

Multiplication-stimulating activity (MSA)
ABSTRACT
produced by Buffalo rat liver cells (BRL-3A) in culture is related
to the somatomedin family of growth regulatory polypeptides.
MSA will stimulate glucose transport and DNA synthesis in
normal chicken embryo fibroblasts (CIEF) at concentrations of
10-200 ng/ml. MSA found in BRL-3A-conditioned medium, like
the somatomedins in serum, does not exist as the free hormone
but is' bound to a specific high molecular weight carrier protein.
In this report we demonstrate that purified MSA carrier protein
(MCP) inhibits the biological activity of MSA on CEF as measured by the stimulation of glucose transport and'DNA synthesis.
In addition, purified MCP competitively inhibits the binding
of i25I1abeled MSA to these cells. In control experiments in
which insulin was used as the mitogenic agent, MCP had no
effect on these biological responses. These results indicate that
the inhibitory effect of MCP'is the result of'specific interaction
with MSA and support the hypothesis that cells may be unresponsive to somatomedins bound to their serum carrier proteins.

MCP added to the culture. Receptor-binding experiments
demonstrated that this inhibition was solely caused by the inhibition of MSA binding to cell-surface growth receptors. Insulin-stimulated DNA synthesis, which is probably mediated
through the same set of receptors (13, 16-19), was unaffected
by the presence of MCP, indicating that the inhibition of the
biological activity of MSA was highly specific.
MATERIALS AND METHODS
Purification of MCP. Details of the purification and characterization of MCP from BRL-3A-conditioned medium have
been presented in a preliminary report (20). Briefly, the source
used for the purification of MCP was a previously discarded
fraction from the purification scheme of MSA. The first step
in this procedure is ion-exchange chromatography with Dowex
50W-X8 resin in the sodium form. MSA binds to the column
at neutral pH and subsequently is eluted at pH 11. Dulak and
Shing (14) first noted from amino acid composition data that
MSA is too acidic to behave in this manner itself and probably
binds to the resin indirectly through more basic proteins in the
conditioned medium. Both MSA and MCP are eluted in the pH
11 fraction and subsequently are dissociated by dialysis against
1 M acetic acid and then separated by Sephadex G-50 chromatography in 1 M acetic acid. MSA elutes from the column
in the retarded fractions, whereas MCP is found in the void
volume. The void-volume fractions are pooled, concentrated
by lyophilization, and resuspended in phosphate-buffered saline. In the major purification step, this preparation is applied
to an affinity column containing a mixture of immobilized MSA.
polypeptides covalently linked to the N-hydroxysuccinimide
ester of Sepharose 4B prepared as described (21). MCP associates with the immobilized MSA and, after thorough washing,
is eluted with 0.1 M acetic acid. The eluted MCP is concentrated by lyophilization and rechromatographed over Sephadex
G-50 in 1 M acetic acid to ensure removal of residual MSA

The somatomedins are small polypeptide hormones that are the
proposed mediators of the action of growth hormone on peripheral tissue (1-3). They are unique among polypeptide
hormones in that they circulate in plasma bound to larger
specific carrier proteins (4-9). Two forms of somatomedincarrier protein complexes have been identified in both human
and rat serum (Mr t 60,000 and Mr 200,000), the larger of
which is growth hormone dependent (7, 8). Both forms of the
complex are pH dependent and readily dissociate at pH values
below 5.5 (5, 6, 8, 9).
Highly purified multiplication-stimulating activity (MSA)
is a somatomedin analog purified from serum-free medium
conditioned by the growth of buffalo rat liver cells (BRL-3A)
in vitro (10-15). Studies utilizing 125I-labeled MSA (125I-MSA)
have demonstrated that MSA specifically binds to somatomedin
carrier proteins present in both human and rat serum (8, 9). In
addition to producing MSA polypeptides in culture, BRL-3A
cells also produce an MSA carrier protein (MCP) that appears
to be strikingly similar in size to the low Mr carrier (Mr
60,000) present in serum (9). We have utilized purified MSA
and purified MCP from BRL-3A-conditioned medium as a
model system to address the question of the biological role of
somatomedin carrier protein(s). In this report we demonstrate
that MCP binds to MSA in such a way as to biologically inactivate it. When equimolar quantities of MCP and MSA were
added to quiescent cultures of chicken embryo fibroblasts
(CEF), there was a 95-100% reduction in the stimulation of
DNA synthesis that normally is seen when MSA alone is added.
When the concentration of MSA was held constant, this inhibition was directly dependent on the concentration of purified
-

polypeptides.
The purified MCP migrates as a single band upon electrophoresis in acetic acid/urea (Fig. 1) and specifically binds
125I-MSA, generating a complex with an apparent Mr of
60,000-70,000 as determined by Sephadex G-200 gel filtration
in saline (data not shown). MCP also migrates as a single band
in NaDodSO4/polyacrylamide gels under nonreducing conditions with an apparent Mr of 31,500. In the presence of 2mercaptoethanol, two closely migratory bands are observed
with Mrs between 30,000 and 32,000.
The MSA used in this report was purified by established
procedures using preparative-scale disc gel polyacrylamide
electrophoresis in acetic acid/urea at pH 2.7 (13-15). Purified
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MSA consisted of a single species, Mr 9000, which probably
corresponds to MSA polypeptide II-1 in the designation system
of Moses et al. (15). MSA was active in stimulating DNA synthesis in quiescent CEF at concentrations of 10-200 ng/ml.
Cell Culture. Primary cultures of CEF were prepared from
the body walls of 9- to 10-day-old chicken embryos as described
(12, 22). The cultures were maintained in Dulbecco's modified
Eagle's medium supplied with 10% calf serum, penicillin (100
units/ml) and streptomycin sulfate (100 ug/ml) in a 5%
C02/95% humidified atmosphere at 370C. Experimental
cultures were prepared by trypsinizing primary cultures and
replating at a density of 3 X 105 cells per plate or 1 X 106 cells
per plate in the medium described above with 0.25% calf serum
in 35-mm or 60-mm cell culture dishes (Lux), respectively.
These cultures were used for experiments 3-4 days later, when
they had reached quiescence.
2[3H]Deoxyglucose Uptake. Rates of glucose uptake were
determined in 35-mm cultures 4 hr after exposure to mitogens
(22). Triplicate cultures were pulse-labeled with 1 /ACi (1 Ci =
3.7 X 1010 becquerels) of 2-[3H]deoxyglucose (8 Ci/mmol; New
England Nuclear) in glucose-free Earle's balanced salt solution
for 15 min at 370C. Uptake rates were linear for 4 times the
pulse period used. At the end of pulse, the cultures were rapidly
rinsed two times, drained, and lysed with 1 ml of 1% NaDodS04. Aliquots were assayed for 3H.
Electrophoresis. Protein samples subjected to electrophoresis
were first Iyophilized to dryness and resuspended in 0.05 ml of
4 M acetic acid/8 M urea containing 0.01% methylene blue as
tracking dye. Samples were applied to tube gels (0.5 X 8.0 cm)
of the following composition: 4M acetic acid/8M urea/7.5%
(wt/vol) acrylamide/0.25% N,N'-methylenebisacrylamide,
0.5% N,N,N',N'-tetramethylethylenediamine and 0.21% ammonium persulfate. Electrophoresis was carried out toward the
cathode at a constant current of 1.5 mA per tube for 4-6 hr at
22°C. Gels were stained in a solution of 0.05% Coomassie blue
(R-250) in methanol/acetic acid/H20, 5:1:5 (vol/vol), for 2.0
hr at 37°C. The gels were destained in 7.5% (vol/vol) acetic acid
containing 20% (vol/vol) methanol. All electrophoresis reagents
were purchased from Bio-Rad.
1251-Labeled MSA Binding. 125I-Labeled MSA (125I-MSA)
was prepared to a specific activity of 60-100 Ci/g by a modification of the chloramine-T procedure as described (16).
Binding to growth receptors in cultures of quiescent chicken
embryo fibroblasts (2.5 X 106 cells per 60-mm plate) was determined as described (22). Briefly, triplicate cultures of cells
were rinsed four times with phosphate-buffered saline and 1
ml of 0.1 M Hepes-buffered Dulbecco's modified Eagle's medium, pH 7.8, containing bovine serum albumin (10 mg/ml)
was added. 125I-MSA (105 cpm; zt~1 ng) was added, and cultures
were incubated for 3 hr at 22°C in the absence or presence of
various concentrations of highly purified or partially purified
MCP. Cultures were then rinsed four times with cold saline and
lysed by the addition of 2 ml of 1.0% NaDodSO4. Aliquots were
assayed for cell-associated radioactivity by liquid scintillation
spectrometry.
Competitive Binding Assay. Competitive binding of 125[MSA to purified MCP was performed using fatty acid-free
bovine serum albumin/activated charcoal to separate bound
from free MSA as described (9). Purified MCP (40 ng) was incubated with 500 pg of 125I-MSA and concentrations of unlabeled MSA ranging from 5-800 ng/ml for 3 hr in 0.4 ml of saline containing 5 mg of albumin per ml. At the end of the incubation period, bound MSA was separated from free MSA and
the supernatants were assayed for radioactivity by liquid
scintillation spectrometry.

Proc. Natl. Acad. Sci. USA 77 (1980)
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RESULTS
Effect of MCP on MSA-Stimulated DNA Synthesis in
Quiescent Cultures of CEF. The effect of highly purified MCP
and partially purified MCP was investigated. The relative
complexities of the MCP preparations are shown in Fig. 1, lanes
A-D, which are gel profiles of the different stages of MCP
purification. The material designated as partially purified MCP
(Fig. 1, lane C), was shown to be free of MSA polypeptides but
included several high M proteins. Highly purified MCP (Fig.
1, lane D) appeared as one protein band in this gel system. In
NaDodSO4/polyacrylamide gels, this band was further resolved
into two distinct proteins with apparent Mrs of 30,000 and
31,500.
It has been reported that MCP in BRL-3A-conditioned medium specifically binds MSA with a higher affinity than does
the somatomedin receptor on CEF (9). Therefore, we examined
the effect of MCP on the biological activity of MSA (Fig. 2).
Quiescent cultures of CEF were simultaneously exposed to MSA
(150 ng/ml, the maximally active dose) and concentrations of
partially purified or highly purified MCP ranging from 0 to 10
Aug/ml (Fig. 2A) or from 0 to 1.6 ,ug/ml (Fig. 2B), respectively.
In both cases, [3H]thymidine incorporation at 12 hr was reduced
in a dose-dependent fashion. At a concentration of 4 yg/ml of
partially purified MCP or a concentration of 1.0 Ag/ml of
highly purified MCP, there was a 96% reduction in [3H]thymidine incorporation. In the reverse experiment in which increasing concentrations of MSA were added to cultures containing purified MCP (500 ng/ml), MSA could overcome the
inhibition at concentrations greater than 200 ng/ml.
The data from Fig. 2 was replotted as percent inhibition of
[3H]thymidine incorporation relative to the concentration of
MCP added (Fig. 3). First, this replot shows that the highly
purified MCP preparation was approximately 6 times more
pure than the partially purified preparation, based on the relative concentrations of each required to cause a 50% inhibition

A BC

D

FIG. 1. 4 M acetic acid/8 M urea gel
electrophoresis of MCP at different stages
of purification. Lanes: A, BRL-3A-conditioned medium proteins, 30 ltg; B,
Dowex-50 MSA, 30 jtg; C, partially purified MCP, 10 ,g; and D, highly purified
MCP 5 fig.
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FIG. 2. Effect of MCP on MSA-stimulated DNA synthesis in
cultures of quiescent CEF as a function of MCP concentration. Cultures of quiescent CEF were incubated in Dulbecco's modified Eagle's
medium with MSA (150 ng/ml) and various concentrations of partially
purified MCP (A) or highly purified MCP (B). Rates of DNA synthesis in duplicate cultures were determined at 12 hr by using a 1-hr
pulse of [3H]thymidine (0.2 MCi/ml). - - -, Background levels of DNA
synthesis in quiescent cultures with media changed to serum-free
Dulbecco's at the start of the experiment.

of [3H]thymidine incorporation. Second, maximal inhibition
was seen at a purified MCP concentration of 1 ,ug/ml. The MSA
polypeptide used in these experiments had a Mr = 9000 and
MCP had a Mr 60,000. With the assumption that MSA and
MCP bind in a 1:1 molar ratio, the experimentally determined
concentration of MCP required to achieve maximal inhibition
(1 ,qg/ml) at an MSA concentration of 150 ng/ml is close to
what one would predict theoretically if MSA bound to MCP is
biologically inactivated.
Scatchard Analysis of MSA Binding to Purified MCP.
Because the data in Figs. 2 and 3 suggested that MSA and MCP
bind in a 1:1 molar ratio, a competitive binding assay was
performed using the fatty acid-free bovine serum albumin/
activated charcoal procedure described by Moses et al. (9).
Scatchard analysis (23) of the results (Fig. 4) yielded an affinity
constant of 0.23 X 109 M-1. This value is similar to that reported
for the binding of MSA to normal rat serum and to BRL3A2-conditioned medium (9). As others have reported (16),
MSA tracer prepared by the chloramine-T procedure contains
a significant amount of damaged unbindable molecules. When

4
2
MSA bound, ng/ml

6

FIG. 4. Scatchard analysis of MSA binding to MCP. Equal
quantities of MCP (40 ng) were incubated with 500 pg of 125I-MSA
and increasing concentrations of unlabeled MSA. The slope of the line
was determined by linear regression analysis.

this is taken into account, the data in Fig. 4 is also consistent with
the conclusion that MSA and MCP bind in a 1:1 molar ratio.
Inhibition of 125I-MSA Binding to Somatomedin Receptors
on CEF by MCP. To more critically evaluate the molecular
nature of MSA inactivation by MCP, receptor binding studies
were performed. Concentrations of highly purified and partially purified MCP ranging from 1 to 500 ng/ml and 0.02 to
2 ,g/ml, respectively, were tested for their effect on receptor
binding. A representative experiment (Fig. 5) shows that both
MCP preparations were able to completely inhibit the specific
binding of 125I-MSA to somatomedin receptors on CEF. Concentrations of 10 and 90 ng/ml of highly purified and partially
purified MCP, respectively, were required to effect a 50%
decrease in specific binding. This 9-fold difference correlates
well with the biological data in Fig. 3, in which a 6-fold higher
concentration of the partially purified MCP preparation was
required to cause a 50% decrease in DNA synthesis. These results strongly suggest that MCP exerts its action by binding MSA
and blocking its association with somatomedin receptors on
CEF, rather than interacting with the cells or receptor sites per
se.
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FIG. 5. MCP-mediated inhibition of 125I-MSA specific binding
to somatomedin receptors on quiescent CEF. Cultures of quiescent
CEF (60-mm dishes; 2.5 X 106 cells per dish) were incubated for 3 hr
at 220C with 105 cpm of 125I-MSA (-1 ng/ml) and various concentrations of highly purified MCP (0) or partially purified (o) MCP.
Cultures were processed for cell-associated l25I-CPM and data was
corrected for nonspecific binding and plotted as % 125I-MSA bound
vs. MCP concentration (log scale). The 100% point (cultures that received '251-MSA only) corresponds to 1.2% of the total input tracer
that was bound (1.2 X 103 cpm). Specific binding was 70% of the total
10-3
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1 0-'

100
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FIG. 3. Inhibition of MSA-stimulated DNA synthesis in cultures
of quiescent CEF as a function of MCP concentration (logarithmic
scale). The data shown in Fig. 2 A and B were replotted to obtain the
sigmoid curves shown. 0, Highly purified MCP; 0, partially purified.
The 50% inhibition points are 0.2 ,ug/ml and 1.2 ,ug/ml for highly purified MOP and partially purified MOP, respectively.

bound tracer.
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Effect of MCP on Insulin-Stimulated DNA Synthesis and
Glucose Uptake. Insulin and MSA elicit similar biological responses when added to quiescent cultures of CEF and presumably mediate their action through the same cell-surface
receptors (12, 13, 16-19). A higher concentration of insulin is
usually required to elicit the same level of response as MSA.
Thus, any agent that affects the cellular receptor sites would
be expected to alter the subsequent biological responses,
whether insulin or MSA is used as the mitogenic agent. To
demonstrate that the action of MCP is not mediated through
nonspecific inhibition of cellular processes or through receptor-site alteration or blockage, two types of experiments were
performed using MSA or insulin as mitogenic agents, in which
the biological responses were measured. In the first of these
experiments, quiescent cultures of CEF were mitogenically
stimulated with insulin (1 ,g/ml) and concentrations of MCP
far in excess of that required to completely inhibit the mitogenic
response of these cells to a maximally active dose of MSA (150
ng/ml). Fig. 6 clearly shows that MCP has little or no effect on
the ability of insulin to stimulate DNA synthesis in these cultures. At the highest concentrations of MCP tested, which were
respectively 2.5- and 5-fold excesses of the amounts of partially
purified and highly purified MCP required to completely inhibit the MSA response, only a slight and insignificant reduction
in the stimulation of DNA synthesis was observed.
In the second type of experiment, with a protocol nearly
identical to that in Fig. 6, the effect of MCP on MSA- and insulin-stimulated uptake of 2-[3H]deoxyglucose was tested.
Glucose uptake was chosen because it is an event that is stimulated early after the addition of mitogen, in contrast to DNA
synthesis, which peaks 12 hr after mitogenic stimulation. MCP
had no effect on insulin-stimulated glucose uptake, but was able
to cause more than 70% reduction in MSA-stimulated cultures
at identical concentrations (Fig. 7).
Effect of Preincubation with MCP. When quiescent cultures were preincubated for up to 12 hr with purified MCP and
then mitogenically stimulated with MSA, a 100% inhibition of
[3H]thymidine incorporation was still observed. In contrast,
8

4.1 4.2 3.9 4.3 3.9
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MCP, gg/ml
FIG. 6. Effect of MCP on insulin-stimulated DNA synthesis in
cultures of quiescent CEF. Triplicate cultures of quiescent CEF were
incubated in Dulbecco's modified Eagle's medium containing insulin
(1 Ag/ml, bars A through E) and partially purified MCP (bars B and
C) or highly purified MCP (bars D and E) at the indicated concentrations. Cultures represented by bar A received insulin only. Control-culture (con.) media were changed to serum-free Dulbecco's only
at the beginning of the experiment. Rates of DNA synthesis were
determined as described in Fig. 2. Fold increases in [PHjthymidine
incorporation relative to control cultures are indicated above the bars.
Each bar represents the mean + SD.
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FIG. 7. Effect of MCP on insulin- and MSA-stimulated glucose
uptake in quiescent cultures of CEF. Triplicate cultures of CEF were
incubated in Dulbecco's modified Eagle's medium containing insulin
(1 Ag/ml; Left, bars A-C) or MSA (150 ng/ml; Right, bars A-C).
Control-culture (con.) media were changed to serum-free Dulbecco's
only at the start of the experiment. To cultures B and C (Left and
Right), highly purified MCP was added at the indicated concentrations. 2-[3H]Deoxyglucose uptake was determined at 4 hr with a
15-min pulse (1 ,Ci/ml) in a glucose-free Eagle's balanced salt solution
at 370C. The percent inhibitions of 2-[3H]deoxyglucose uptake in
cultures that received MCP (Left and Right, bars B and C), relative
to cultures that received only insulin (Left, bar A) or MSA (Right, bar
A) are indicated above the bars. Each bar represents the mean ±
SD.

when the cells were preincubated for 12 hr with MCP and then
washed prior to MSA addition, there was no inhibition of
[3H]thymidine incorporation. These results (Table 1) demonstrate that preincubation with MCP has no direct inhibitory
effect on the ability of the cells to respond to MSA.

DISCUSSION
In these studies we demonstrated that the mitogenic action of
MSA on quiescent cultures of CEF is strongly inhibited in a
dose-dependent fashion by the presence of MCP in the culture
medium. At a MSA concentration where the mitogenic response
was maximal, an equimolar amount of purified MCP caused
a 96% reduction in the stimulation of DNA synthesis. In control
experiments in which insulin was substituted for MSA as the
mitogenic agent, concentrations of MCP far in excess of those
required to completely inhibit the MSA mitogenic response had
little or no effect on insulin-stimulated DNA synthesis or glucose
transport. Because MSA and insulin effect their action on CEF
through the same set of cell-surface receptors (13, 16-19), this
Table 1. Effect of preincubation of quiescent cultures of CEF
with MCP prior to MSA stimulation
MCP presence
MSA
PreMSA
3H-thymidine,
%
stimulation incubation stimulation cpm per culture inhibition
_

-

-

4,791 ± 718
11,646 + 275
+
100%
3,617+586
+
+
2,033 + 177
100%
+
0%
11,892 ± 781
Triplicate cultures of quiescent CEF were stimulated with MSA
(150 ng/ml) in the presence (+) or absence (-) of MCP (5 Ag/ml).
Some of the cultures had also been preincubated for a 12-hr period
with MCP at the same concentration. Levels of [:IHlthymidine incorporation were determined 12 hr after MSA addition and the percent inhibition determined. Data shown is the mean A SD.

+
+
+
+
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suggested that the inhibitory action of MCP was due to a specific interaction between MSA and MCP directly, rather than
an interaction between MCP and cell-surface receptors per se.
Support of this hypothesis was obtained in subsequent experiments, in which it was demonstrated that MCP was able to
completely block the specific binding of 125I-MSA to CEF somatomedin receptors. Because we and others (9) have shown
that MCP specifically binds MSA with a high affinity, our results strongly suggest that MCP binds to MSA in such a way as
to block its ability to interact with cell-surface receptor sites by
either binding to the active site or sterically masking its availability.
The only documented function of somatomedin carrier
protein(s) is that it increases the circulating half-life of injected
somatomedin activity from a few minutes to several hours (7).
In studies similar to this one, designed to investigate the effect
of somatomedin carrier protein(s) on the biological activity of
somatomedins, it was shown that nonsuppressible insulin-like
activity bound to its partially purified carrier was ineffective
in stimulating glucose transport and lipogenesis in rat fat cells
(24) and insulin-like effects on perfused rat heart (25). Somatomedin-binding proteins from amniotic fluid have also been
shown to inhibit the stimulation of thymidine uptake by human
fibroblasts and sulfate incorporation by rabbit chrondrocytes
(26, 27). In contrast, it was suggested by Froesch et al. (28) that
fibroblasts and chondrocytes may possess a unique mechanism
that allows them to utilize somatomedins in their carrier-bound
form. The results of the present study clearly demonstrate that
this is not the case with CEF. It should also be pointed out that
our results are not an artifact due to an alteration of MCP during
the purification procedure. Other investigators have shown that
MCP in BRL-3A-conditioned medium binds MSA with the
same affinity before and after exposure to 1 M acetic acid (9),
which is the harshest step used in our purification procedure.
We feel that the use of highly purified MSA carrier protein
from BRL-3A-conditioned medium provides a unique opportunity to investigate the biological role of somatomedin carrier
protein(s), and should greatly facilitate further studies.
Since we have demonstrated that MSA bound to its carrier
protein is biologically inactive in stimulating DNA synthesis
in CEF, it appears paradoxical that these cells are stimulated
by BRL-3A-conditioned medium or serum, in which the MSA
or somatomedin exists primarily in the bound form. In the case
of conditioned medium, it is apparent that free MSA is in excess.
This is shown by the fact that when 125I-MSA is incubated with
conditioned medium and then fractionated on Sephadex G-200
at neutral pH, all of the radioactivity remains as free MSA.
Serum, however, has specific MSA-binding sites available in
two high Mr complexes (8,9). The MSA complex described in
the report is similar in size to the low Mr complex in serum,
which may be a precursor to the higher Mr form (6). It is conceivable that the larger Mr complex is active and serves as a
delivery system for cell utilization. Alternately, CEF may respond to other insulin-like growth factors in serum similar to
that described by Poffenbarger (29).
The excellent technical assistance of Ms. Russette Lyons is gratefully
acknowledged. We also wish to thank Dr. Fred W. Wagner for his
expert assistance in the preparation of the affinity chromatography
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